|  |
| --- |
| **Supplementary Table 1. Baseline characteristics** |
| Characteristics | Low HBV-DNA cohort (n=429) |  | High HBV-DNA cohort (n=493) |
| ETV (n=366) | TDF (n=63) | P Value | ETV (n=440) | TDF (n=53) | P Value |
| Age >60 years (%) | 95 (26.0) | 7 (11.1) | 0.017 |  | 109 (24.8) | 11 (20.8) | 0.635 |
| Male (%) | 312 (85.2) | 54 (85.7) | 1.000 |  | 362 (82.3) | 43 (81.1) | 0.988 |
| BMI, kg/m2 | 22.8 [21.1, 25.2] | 23.4 [21.4, 25.7] | 0.431 |  | 23.1 [20.8, 24.9] | 22.9 [21.2, 26.0] | 0.425 |
| Hypertension (%) | 102 (27.9) | 11 (17.5) | 0.115 |  | 135 (30.7) | 13 (24.5) | 0.444 |
| Diabetes mellitus (%) | 44 (12.0) | 9 (14.3) | 0.766 |  | 59 (13.4) | 7 (13.2) | 1.000 |
| HBeAg positive (%) | 44 (12.0) | 12 (19.0) | 0.185 |  | 131 (29.8) | 14 (26.4) | 0.728 |
| AFP >400 ng/ml (%) | 126 (34.4) | 19 (30.2) | 0.605 |  | 179 (40.7) | 24 (45.3) | 0.62 |
| INR | 1.04 [0.99, 1.09] | 1.04 [1.00, 1.11] | 0.274 |  | 1.05 [1.00, 1.11] | 1.04 [1.00, 1.10] | 0.926 |
| PLR> 102.9 (%) | 119 (32.5) | 25 (39.7) | 0.333 |  | 190 (43.2) | 19 (35.8) | 0.382 |
| NLR>2.6 (%) | 116 (31.7) | 18 (28.6) | 0.729 |  | 157 (35.7) | 13 (24.5) | 0.144 |
| ALT> 40U/L (%) | 104 (28.4) | 20 (31.7) | 0.698 |  | 226 (51.4) | 26 (49.1) | 0.863 |
| AST> 40U/L (%) | 99 (27.0) | 16 (25.4) | 0.905 |  | 236 (53.6) | 19 (35.8) | 0.021 |
| ALB>40g/L (%) | 289 (79.0) | 60 (95.2) | 0.004 |  | 298 (67.7) | 38 (71.7) | 0.667 |
| TBIL>28μmol/L (%) | 20 (5.5) | 1 (1.6) | 0.317 |  | 14 (3.2) | 2 (3.8) | 1.000 |
| Tumor size, cm | 4.0[2.8, 6.0] | 4.0 [2.3, 7.0] | 0.462 |  | 5.0 [3.4, 8.6] | 4.0 [3.0, 5.5] | 0.002 |
| Multiple tumor (%) | 9 (2.5) | 4 (6.3) | 0.206 |  | 6 (1.4) | 1 (1.9) | 1.000 |
| Cirrhosis (%) | 301 (82.2) | 51 (81.0) | 0.946 |  | 375 (85.2) | 43 (81.1) | 0.561 |
| MVI (%) | 68 (18.6) | 14 (22.2) | 0.613 |  | 112 (25.5) | 15 (28.3) | 0.778 |
| Capsular invasion (%) | 163 (44.5) | 33 (52.4) | 0.309 |  | 183 (41.6) | 23 (43.4) | 0.917 |
| Satellite nodules (%) | 43 (11.7) | 3 (4.8) | 0.151 |  | 44 (10.0) | 4 (7.5) | 0.746 |
| Tumor differentiation (%) |  |  |  |  |  |  |  |
| Low | 159 (43.4) | 34 (54.0) |  |  | 190 (43.2) | 29 (54.7) |  |
| Intermediate | 199 (54.4) | 28 (44.4) | 0.299 |  | 247 (56.1) | 23 (43.4) | 0.160 |
| High | 8 (2.2) | 1 (1.6) |  |  | 3 (0.7) | 1 (1.9) |  |
| Patients with decreased HBV-DNA load at year 1 (%)\* | 342 (93.4) | 61 (96.8) | 0.400 |  | 433 (98.4) | 53 (100) | 1.000 |
| \*The decrease rates of HBV-DNA load in the TDF and ETV groups were 98.3% and 96.2%, respectively, at year 1.Abbreviations: ETV, entecavir; TDF, tenofovir disoproxil fumarate; BMI, body mass index; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; AFP, alpha-fetoprotein; TBIL, Total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; INR, international normalized ratio; PLR, platelet to [lymphocyte](https://fanyi.so.com/?src=onebox" \l "lymphocyte" \t "https://www.so.com/_blank) ratio; NLR, neutrophil to [lymphocyte](https://fanyi.so.com/?src=onebox" \l "lymphocyte" \t "https://www.so.com/_blank) ratio; MVI, microvascular invasion. |